BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
-2.44%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$150M
AUM Growth
+$150M
(-8.7%)
Cap. Flow
-$5.68M
Cap. Flow
% of AUM
-3.78%
Top 10 Holdings %
Top 10 Hldgs %
87.14%
Holding
55
New
1
Increased
10
Reduced
3
Closed
5
Top Buys
| 1 |
EQM
EQM Midstream Partners, LP
EQM
|
$1.68M |
| 2 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
$499K |
| 3 |
KalVista Pharmaceuticals
KALV
|
$348K |
| 4 |
Myriad Genetics
MYGN
|
$286K |
| 5 |
XBiotech
XBIT
|
$209K |
Top Sells
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$7.78M |
| 2 |
Atara Biotherapeutics
ATRA
|
$402K |
| 3 |
Veracyte
VCYT
|
$360K |
| 4 |
Nektar Therapeutics
NKTR
|
$338K |
| 5 |
Apellis Pharmaceuticals
APLS
|
$203K |
Sector Composition
| 1 | Healthcare | 96.12% |
| 2 | Energy | 2.68% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Materials | 0.04% |
| 5 | Consumer Staples | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Apellis Pharmaceuticals
APLS
$3.56B
| – | – |
-8,000
| Closed | -$203K |
|
|
52
Atara Biotherapeutics
ATRA
$86.7M
| – | – |
-20,000
| Closed | -$402K |
|
53
EQT Corp
EQT
$32.7B
| – | – |
-11,300
| Closed | -$179K |
|
|
54
Nektar Therapeutics
NKTR
$553M
| – | – |
-9,500
| Closed | -$338K |
|
|
ARRY
55
DELISTED
Array Biopharma Inc
ARRY
| – | – |
-168,000
| Closed | -$7.78M |
|